AMGN vs. VTRS: Amgen vs. Viatris Stock Comparison
How do Amgen (AMGN) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Amgen (AMGN) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while VTRS is classified in Pharmaceuticals.
| Profile Item | AMGN | VTRS |
|---|---|---|
| Name | Amgen Inc. Common Stock | Viatris Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 249.05 billion USD | 22.83 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 17, 1983 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AMGN | VTRS |
|---|---|---|
| Total Return (1Y) | 48.82% | 108.98% |
| Total Return (3Y, Annualized) | 24.31% | 36.75% |
| Total Return (5Y, Annualized) | 20.67% | 11.59% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AMGN | VTRS |
|---|---|---|
| Volatility (1Y, Annualized) | 29.12% | 32.53% |
| Beta (5Y) | 0.43 | 0.86 |
| Max Drawdown (5Y) | -24.86% | -45.69% |
| Avg. Volume (3M) | 2.76M | 8.87M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AMGN | VTRS |
|---|---|---|
| Sharpe Ratio (1Y) | 1.53 | 3.22 |
| Sortino Ratio (1Y) | 2.36 | 5.63 |
Profitability
ROE (TTM)
Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Amgen (AMGN) reports 78.35%, ranking against industry peers normally.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
78.35%
- Max
- 109.18%
- AMGN
- 78.35%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.21%
- Max
- 109.18%
- Q3
- 6.23%
- VTRS
- -4.21%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Amgen (AMGN) reports 24.14%, ranking against industry peers normally.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.14%
- AMGN
- 24.14%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.13%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- VTRS
- -4.13%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Amgen (AMGN) at 35.79% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.79%
- Max
- 83.12%
- AMGN
- 35.79%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.85%
- Max
- 83.12%
- Q3
- 14.77%
- VTRS
- 13.85%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AMGN | VTRS |
|---|---|---|
| ROE (TTM) | 78.35% | -4.21% |
| ROA (TTM) | 8.91% | 2.91% |
| Net Margin (TTM) | 24.14% | -4.13% |
| Operating Margin (TTM) | 35.79% | 13.85% |
| Gross Margin (TTM) | 72.47% | 41.13% |
Growth
Revenue Growth
Amgen (AMGN) at 9.95% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Amgen (AMGN) reports EPS growth of 88.23%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.
Growth Metrics
| Metric | AMGN | VTRS |
|---|---|---|
| Revenue Growth (YoY) | 9.95% | -2.98% |
| Revenue Growth (3Y CAGR) | 11.77% | -4.20% |
| EPS Growth (YoY) | 88.23% | -- |
| EPS Growth (3Y CAGR) | 5.52% | -- |
Financial Strength
Current Ratio (MRQ)
Both Amgen (AMGN) at 1.48 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AMGN
- 1.48
- Min
- 0.10
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- VTRS
- 1.55
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but AMGN is more stretched: Viatris (VTRS) at 0.99 sits in the higher-leverage quartile and Amgen (AMGN) at 3.76 is above its industry benchmark range.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.76
- AMGN
- 3.76
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.99
- Max
- 1.42
- VTRS
- 0.99
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AMGN | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 1.48 | 1.55 |
| Debt / Equity (MRQ) | 3.76 | 0.99 |
| Net Debt / EBITDA | 2.31 | 2.64 |
Dividends
Dividend Yield (TTM)
Both Amgen (AMGN) at 2.16% and Viatris (VTRS) at 2.53% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.16%
- AMGN
- 2.16%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.53%
- VTRS
- 2.53%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Amgen (AMGN) reports 57.62%, ranking against industry peers normally.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
57.62%
- AMGN
- 57.62%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
960.00%
- VTRS
- 960.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AMGN | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 2.16% | 2.53% |
| Dividend Payout Ratio (TTM) | 57.62% | 960.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Amgen (AMGN) trades at 26.69 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.69
- Max
- 85.34
- Q3
- 43.46
- AMGN
- 26.69
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- VTRS
- --
P/S Ratio (TTM)
Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Amgen (AMGN) at 6.40 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.40
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- AMGN
- 6.40
- Q1
- 3.01
- Min
- 0.01
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- VTRS
- 1.55
- Min
- 0.01
P/B Ratio (MRQ)
Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile relative to book while Amgen (AMGN) at 17.35 prices above its industry range — a wide valuation gap against assets.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.35
- AMGN
- 17.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- VTRS
- 1.67
- Min
- -5.59
Valuation Metrics
| Metric | AMGN | VTRS |
|---|---|---|
| P/E Ratio (TTM) | 26.69 | -- |
| P/S Ratio (TTM) | 6.40 | 1.55 |
| P/B Ratio (MRQ) | 17.35 | 1.67 |
| Free Cash Flow Yield (TTM) | 2.96% | 13.84% |